News from IAS 2011

The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) took place in Rome, Italy, 17-20th July, with more than 5000 delegates.

As the official online partner for scientific reporting, NAM published six free email bulletins, with original news reporting and links to abstracts.

The conference included an interesting and diverse collection of presentations and sessions, covering a broad range of subjects in the HIV field, including new treatment, prevention and practice research.

This year’s conference had a major focus on treatment as prevention and on the use of antiretrovirals as pre-exposure prophylaxis (PrEP).

All our news reports from the conference are listed here, for the summary bulletins in English, French, Spanish, Portuguese or Russian, visit our conference bulletin page.

aidsmap news from IAS 2011

PrEP acceptable to gay men and few report that it would change their risk behaviour

Approximately 50% of American gay men said they were likely to use pre-exposure prophylaxis (PrEP), but few reported that it would lead to a change in their

Published
10 August 2011
By
Michael Carter
Poor CD4 cell recovery after starting HIV treatment should be a cause for concern, close monitoring needed

Patients whose CD4 cell count does not recover despite achieving virologic control with HIV therapy require continued medical attention, results of a large European study presented to

Published
01 August 2011
By
Michael Carter
Boceprevir response and resistance differs according to HCV genotype 1 subtype

People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a,

Published
28 July 2011
By
Liz Highleyman
Valaciclovir slows HIV disease progression in pregnant and breastfeeding women

Valaciclovir used to suppress herpes simplex virus 2 (HSV-2) in HIV co-infected pregnant and post-partum women in Nairobi, Kenya, slowed HIV disease progression and reduced viral load in

Published
26 July 2011
By
Carole Leach-Lemens
Herpes drugs and viral load: valaciclovir works better than aciclovir

The anti-herpes drug valaciclovir (Valtrex, valacyclovir in the US) produced a 17-fold (1.23 log) reduction in HIV viral load in Kenyan patients not taking treatment, the sixth

Published
26 July 2011
By
Gus Cairns
New integrase inhibitor dolutegravir looks potent and well-tolerated

The next-generation HIV integrase inhibitor dolutegravir (S/GSK1349572) suppressed HIV viral load as well as efavirenz (Sustiva, Stocrin) but caused fewer side-effects in a study of treatment-naive patients, researchers reported

Published
26 July 2011
By
Liz Highleyman
High levels of unmet need for family planning in people with HIV - couples unaware of conception and contraception options

In Kenya, Tanzania and Namibia, just 46% of HIV-positive women and 28% of HIV-positive men have discussed family planning with a healthcare provider, delegates were told at the

Published
26 July 2011
By
Roger Pebody
What's next for HIV prevention? Paying people to be healthy

Researchers are investigating the impact of offering financial incentives to people who are at risk of acquiring or passing on HIV, the International AIDS Society conference (IAS

Published
25 July 2011
By
Roger Pebody
Infant prophylaxis during breastfeeding reduces risk of HIV infection by 71%

Extended use of nevirapine or zidovudine and nevirapine in infants can reduce the risks of HIV transmission through breastmilk by over 70%, Charles van der Horst reported

Published
25 July 2011
By
Carole Leach-Lemens
Another NRTI-sparing regimen does well in treatment-naive patients

A nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir is as safe and effective as a traditional nucleoside-based HIV treatment combination, according to the results of a small

Published
25 July 2011
By
Michael Carter
← First123...4Next →

Coverage of the conference from CCO

Clinical Care Options (CCO) is the other official online partner of the conference. It will be providing audio highlights, capsule summaries and downloadable slidesets and we will link to their coverage in our news and bulletins, so you can have the fullest picture of the conference.

"Ending the epidemic is scientifically doable"

From 'what if' to 'what now': implementing the new prevention technologies.

Read this news story >

Treatment is prevention

HPTN 052 study shows 96% reduction in transmission when HIV-positive partner starts treatment early.

Read this news story >

Hormonal contraception and HIV

Hormonal contraceptive use increases women’s risk of acquiring and transmitting HIV.

Read this news story >

PrEP works for women too

Pre-exposure prophylaxis does work for women, two studies find.

Read this news story >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.